TLS Advisors LLC Has $26,000 Holdings in Ovid Therapeutics $OVID

TLS Advisors LLC lessened its position in Ovid Therapeutics (NASDAQ:OVID) by 97.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,858 shares of the company’s stock after selling 662,109 shares during the quarter. Ovid Therapeutics makes up about 0.1% of TLS Advisors LLC’s holdings, making the stock its 18th biggest holding. TLS Advisors LLC’s holdings in Ovid Therapeutics were worth $26,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in OVID. Apollon Wealth Management LLC acquired a new stake in Ovid Therapeutics during the 3rd quarter valued at $36,000. Jane Street Group LLC acquired a new position in Ovid Therapeutics during the second quarter valued at $47,000. Bank of America Corp DE lifted its stake in Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after acquiring an additional 18,841 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Ovid Therapeutics during the 2nd quarter worth about $53,000. Finally, Velan Capital Investment Management LP boosted its position in Ovid Therapeutics by 64.9% during the 2nd quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company’s stock worth $53,000 after acquiring an additional 63,000 shares during the period. 72.24% of the stock is currently owned by hedge funds and other institutional investors.

Ovid Therapeutics Price Performance

NASDAQ OVID opened at $1.56 on Friday. The company has a quick ratio of 4.24, a current ratio of 4.24 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $111.09 million, a PE ratio of -3.12 and a beta of 0.22. Ovid Therapeutics has a 12-month low of $0.24 and a 12-month high of $2.01. The company has a 50 day moving average price of $1.64 and a two-hundred day moving average price of $1.34.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Ovid Therapeutics had a negative return on equity of 63.79% and a negative net margin of 550.04%.The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.17 million. As a group, equities analysts predict that Ovid Therapeutics will post -0.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on OVID. HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Ovid Therapeutics in a research report on Monday, December 22nd. Lifesci Capital began coverage on shares of Ovid Therapeutics in a research report on Monday, December 22nd. They issued an “outperform” rating and a $4.00 target price for the company. Wall Street Zen lowered shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Oppenheimer started coverage on shares of Ovid Therapeutics in a report on Thursday, October 9th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Roth Mkm began coverage on Ovid Therapeutics in a report on Thursday, December 11th. They set a “buy” rating and a $3.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $3.88.

Ovid Therapeutics Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.